Business
Zealand Pharma Announces Financial Results for the First Nine Months of 2025
Company announcement – No. 23 / 2025 Zealand Pharma Announces Financial Results for the First Nine Months of 2025With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026. Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving the way f
About this update from Zealand Pharma A/s
[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6gUCOEdJjLHihlE.VvDQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Company announcement – No. 23 / 2025","length":36,"tagName":"p"},{"type":"text","content":"Zealand Pharma Announces Financial Results for the First Nine Months of 2025With petrelintide advancing at full speed and topline data rapidly approaching for both petrelintide and survodutide, upcoming Capital Markets Day will set the stage for a catalyst-rich 2026.","length":268,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Achieved key milestone in the petrelintide Phase 2 ZUPREME-1 trial in people with overweight and obesity, with the last participant completing the 28-week primary endpoint visit, paving the way for 42-week topline data in H1 2026.","length":230,"tagName":"p"}]},{"val":[{"type":"text","content":"Approaching Phase 3 data in H1 2026 with survodutide, following last participant last visit in the 76-week SYNCHRONIZETM-1 trial in people with overweight and obesity without type 2 diabetes.","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"Zealand Pharma is excited to outline a catalyst-rich 2026 at its upcoming Capital Markets Day on December 11, highlighting its ambition to become a generational biotech company driving the next wave of innovation in obesity.","length":224,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":645,"olType":false},{"type":"text","content":"Copenhagen, Denmark, November 13, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the interim report for the nine months ended September 30, 2025, and provided a corporate update.","length":312,"tagName":"p"},{"type":"text","content":"Ready for key near-term data catalysts and driving the next wave of innovationAdam Steensberg, President and Chief Executive Officer at ...